Applying Innovative Technology to Develop AlloCAR T™ Therapy



The process for manufacturing our off-the-shelf allogeneic CAR T cell (AlloCART™) therapy first involves harvesting healthy, selected, screened and tested T cells from healthy donors. This means that a larger portion of eligible patients, including those who are critically ill and have T cells that are difficult to harvest or expand, can potentially receive treatment, and no eligible patient will have to undergo leukapheresis (a laboratory procedure in which a patient's white blood cells are separated and the remaining blood cells and plasma are returned to the patient).

Next, the T cells are engineered to express CARs, which recognize certain cell surface proteins that are expressed in hematologic or solid tumors. ALLO-501 and ALLO-501A, two of our investigational therapies, target CD19, while a third, ALLO-715, targets BCMA, cell surface proteins expressed on B-cells, including cancerous B-cells. These are just the first candidates in a line of AlloCAR T™ therapies we plan to develop. The next step in the process involves gene editing to reduce the risk of graft versus host disease (GvHD) and allogeneic rejection. A T cell receptor gene is knocked out with the goal of avoiding GvHD. Knocking out the CD52 gene is expected to render the CAR T product resistant to anti-CD52 antibody treatment. ALLO-647, our proprietary anti-CD52 monoclonal antibody, should therefore be able to suppress the host immune system and potentially allow the AlloCAR T™ to stay engrafted to enhance therapeutic impact.

The engineered T cells then undergo a purification step and are ultimately cryopreserved in vials for delivery to patients.

State-of-the-Art, In-House Manufacturing for Long-Term Clinical and Commercial AlloCAR T™ Production

Building world-class manufacturing capabilities is at the core of our strategy to deliver readily available AlloCARs™ faster, more reliably and at greater scale.

A new manufacturing facility, located in Newark, CA, in San Francisco's East Bay Area, is being designed to provide GMP manufacturing for clinical supply and commercial product upon potential regulatory approval, and will complement Allogene's buildout of in-house process development and characterization capabilities.

Allogene currently manufactures its clinical trial supply through a contract manufacturing organization, which remains a component of our long-term manufacturing strategy.

210 E. Grand Avenue, South San Francisco, CA 94080
Contact Allogene: info@allogene.com

Dec 2020